

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/178149 A3

(51) International Patent Classification:

A61K 38/20 (2006.01) A61K 31/164 (2006.01)
A61K 31/341 (2006.01) A61K 47/00 (2006.01)
A61K 31/7125 (2006.01) A61K 35/12 (2015.01)
A61P 29/00 (2006.01) A61P 25/02 (2006.01)
A61K 31/145 (2006.01)

(21) International Application Number:

PCT/US2022/016828

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/150,453 17 February 2021 (17.02.2021) US

(71) Applicant: **CODIAK BIOSCIENCES, INC.** [US/US]; 35
CambridgePark Drive, Suite 500, Cambridge, Massachu-
setts 02140 (US).

(72) Inventors: **VERMA, Ajay**; c/o Codiak BioSciences, Inc.,
35 CambridgePark Drive, Suite 500, Cambridge, Massachu-
setts 02140 (US). **ECONOMIDES, Kyriakos**; c/o Codi-
ak Biosciences, Inc., 35 CambridgePark Drive, Suite 500,
Cambridge, Massachusetts 02140 (US). **KIRWIN, Katherine**;
c/o Codiak Biosciences, Inc., 35 CambridgePark Drive,
Suite 500, Cambridge, Massachusetts 02140 (US). **LIM,**
Joanne; c/o Codiak Biosciences, Inc., 35 CambridgePark
Drive, Suite 500, Cambridge, Massachusetts 02140 (US).
JANG, Su Chul; c/o Codiak Biosciences, Inc., 35 Cam-
bridgePark Drive, Suite 500, Cambridge, Massachusetts
02140 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

29 September 2022 (29.09.2022)

(54) Title: EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST

(57) Abstract: The present disclosure relates to extracellular vesicles, e.g. exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders, such as, for example, a peripheral neuropathy.

WO 2022/178149 A3